Linezolid-induced peripheral neuropathy in patients receiving MDR-TB treatment
Conclusion: These findings emphasise the need for close monitoring of side effects and careful consideration of treatment duration is required when using linezolid in the treatment of TB. Therapeutic drug monitoring may allow for dose reductions in the future. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Skyllberg, E., Young, R., Sharma, A., Chen, C., Tiberi, S., White, V., Kunst, H. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research
Seventeen drugs, one sample: analyzing multiple anti-TB drugs simultaneously using one method
In conclusion, we developed a method to analyze 17 anti-TB drugs simultaneously in one sample of plasma, serum or saliva: all first-line, BPaLM, and 9m all oral regimen for MDR/RR-TB drugs, and 63% of the longer MDR-TB regimen drugs. This method will save time and will further optimize therapeutic drug monitoring. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Bolhuis, M. S., Jongedijk, E. M., Akkerman, O. W., Touw, D. J., Sturkenboom, M. G. G. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research
Tuberculous meningoencephalitis complicate with mielitis
Conclusions: Patients with myelitis often have poor outcomes. In the presented case, the patient had a favorable clinical response to the treatment, but despite the correctly administered antituberculous treatment, the inflammation in the CSF continues to persist. Further research on the pathogenesis of TB myelitis will be helpful to provide potential effective therapy to these patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Caliman-Sturdza, O. A. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research
Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents
Expert Rev Anti Infect Ther. 2023 Oct 24. doi: 10.1080/14787210.2023.2275663. Online ahead of print.ABSTRACTINTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in the hospital setting and causes significant morbidity and mortality each year. Since the initial discovery over 60 years ago, vancomycin has remained a first-line treatment for many different types of MRSA infections. However, significant concerns related to target attainment and nephrotoxicity have spurred efforts to develop more effective agents in the last two decades.AREAS COVERED: Newer anti-MRSA antibiotics that ha...
Source: Expert Review of Anti-Infective Therapy - October 25, 2023 Category: Infectious Diseases Authors: Jack Chang Ardita Tasellari Jamie L Wagner Marc H Scheetz Source Type: research
A Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneously Determining Meropenem and Linezolid in Blood and Cerebrospinal Fluid
Ann Lab Med. 2023 Oct 23. doi: 10.3343/alm.2023.0250. Online ahead of print.ABSTRACTAntibiotic therapy requires appropriate dosage of drugs for effective treatment. Too low antibiotic concentrations may lead to treatment failure and the development of resistant pathogens, whereas overdosing may cause neurological side effects or hemolytic diseases. Meropenem and linezolid are used only in the treatment of serious infections or when other antibiotics are no longer effective as well as for treating central nervous system infections. It is difficult or sometimes even impossible to predict the relation between dosing of antibi...
Source: Annals of Laboratory Medicine - October 23, 2023 Category: Laboratory Medicine Authors: Joanna Berska Jolanta Bugajska Krystyna Sztefko Source Type: research
